CME in Minutes: Education in Primary Care

• Taofeek K. Owonikoko, MD, PhD, MS / Ticiana Leal, MD - New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3–Directed ADCs

  Please visit answersincme.com/860/99097105-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in small cell lung cancer (SCLC) discuss the pathophysiologic rationale, emerging clinical evidence, and potential future role for B7-H3–directed antibody-drug conjugates in extensive-stage SCLC. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating B7-H3–directed antibody-drug conjugates (ADCs) in the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC); Analyze recent clinical trial findings on B7-H3–directed ADCs in patients with previously treated ES-SCLC; and Formulate evidence-based, multidisciplinary team strategies for incorporating B7-H3–directed ADCs into treatment plans for patients with ES-SCLC, as they become available.

  --------  

  1:01:35

  --------

  1:01:35
• Nicola Hanania, MD, MS / Surya P. Bhatt, MD, MSPH - Demystifying the Evidence for Biologics in COPD: Strategies for Optimized, Patient-Centered Management

  Please visit answersincme.com/860/MED-RESP-03658-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in pulmonary medicine discuss how to integrate biologics into individualized treatment plans for chronic obstructive pulmonary disease (COPD), featuring insights from a patient advocate. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting eosinophilic inflammation in COPD; Differentiate available and late-stage emerging biologic therapies based on the latest clinical evidence in COPD; Identify patients with COPD who are appropriate candidates for biologic therapy; and Outline strategies to optimally incorporate biologic therapies into treatment plans for patients with COPD.

  --------  

  1:04:43

  --------

  1:04:43
• Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us?

  Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.

  --------  

  18:49

  --------

  18:49
• Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

  Please visit answersincme.com/860/99534447-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

  --------  

  1:01:30

  --------

  1:01:30
• Stella Lee, MD / Kathleen Buchheit, MD - Striving for Patient Satisfaction in the Present and Future: Personalizing Treatment in an Evolving Paradigm

  Please visit answersincme.com/860/99066167-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in nasal polyps discuss personalizing treatment selection in CRSwNP with emerging biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

  --------  

  31:03

  --------

  31:03

More Health & Wellness podcasts

Trending Health & Wellness podcasts

About CME in Minutes: Education in Primary Care

CME in Minutes: Education in Primary Care: Podcasts in Family